Skip to main content

Animations

MJFF Publications

1711 - 1720 of 8801 Results
Title
Year
  • Year
  • 2018
  • 2024
  • 2013
  • 2019
  • 2021
  • 2025
  • 2022
  • 2025
  • 2016
  • 2012
  • Summary Details
    RESTRICTED
    Title: Consensus for the measurement of the camptocormia angle in the standing patient
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2018.06.013
    Citation Count: 68
  • Summary Details
    RESTRICTED
    Title: Evaluation of Protein Identification and Quantification by the diaPASEF Method on timsTOF SCP
    Journal Name: Journal of the American Society for Mass Spectrometry
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1021/jasms.4c00067
    Citation Count: 3
  • Summary Details
    RESTRICTED
    Title: TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2013.06.005
    Citation Count: 39
  • Summary Details
    OPEN
    Title: Parkinson’s progression prediction using machine learning and serum cytokines
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-019-0086-4
    Citation Count: 98
  • Summary Details
    RESTRICTED
    Title: Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.01.024
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson’s disease
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-025-00896-z
    Citation Count: 0
  • Summary Details
    OPEN
    Title: A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells11061018
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Cyclic Alternating Pattern Dynamics in Individuals at Risk for Developing Parkinson's Disease
    Journal Name: Annals of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/ana.27217
    Citation Count: 1
  • Summary Details
    RESTRICTED
    Title: Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26483
    Citation Count: 41
  • Summary Details
    RESTRICTED
    Title: P1‐021: Diurnal and intersubject variability of cerebrospinal fluid biomarkers, Aβ‐40/42, alpha‐synuclein and DJ‐1 in healthy volunteers
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.jalz.2012.05.296
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.